Female Sexual Satisfaction and Pharmaceutical Intervention: A Critical Review of the Drug Intervention Studies in Female Sexual Dysfunction
- 1 September 2006
- journal article
- review article
- Published by Oxford University Press (OUP) in The Journal of Sexual Medicine
- Vol. 3 (5) , 763-777
- https://doi.org/10.1111/j.1743-6109.2006.00285.x
Abstract
A considerable number of double‐blind randomized controlled studies investigating the effects of pharmaceutical intervention on female sexual functioning have been published in recent years. However, a comparison between outcomes of various studies is difficult as no generally accepted/correct approach to research has been established yet. To be able to translate trial results to daily clinical practice, current limitations and issues in drug intervention studies in female sexual dysfunction (FSD) need to be clarified. To evaluate the needs in research into intervention in FSD by reviewing published studies. A systematic review of double‐blind randomized controlled intervention trials on FSD. Definitions of study populations, inclusion and exclusion criteria, use of power calculations, outcome measures and treatment duration. A total of 25 double‐blind randomized controlled trials investigating the effects of pharmaceutical intervention on female sexual functioning have been published. Of these, 11 studies required the diagnosis of FSD as an inclusion criterion. A standard methodology for research in this field is lacking. Significant differences in population inclusion requirements and tools for the measurement of change in sexual functioning were identified as major limiting factors. The investigation of FSD is an evolving area in that new definitions and a new model for female sexual functioning have been recently proposed. There is a need for experts in the field and regulating authorities to reach a consensus regarding appropriate inclusion and exclusion criteria for FSD trials and main outcome measures appropriate for the evaluation of drug interventions. This consensus should also determine which treatment effect is considered to be clinically relevant. Treatment efficacy and clinical relevance should be related to outcomes which are meaningful for affected women. Nijland E, Davis S, Laan E, and Schultz WW. Female sexual satisfaction and pharmaceutical intervention: A critical review of the drug intervention studies in female sexual dysfunction. J Sex Med 2006;3:763–777.Keywords
This publication has 67 references indexed in Scilit:
- Effects of aromatase inhibition on sexual function and well-being in postmenopausal women treated with testosterone: a randomized, placebo-controlled trialMenopause, 2006
- Correlates of sexual function among multi-ethnic middle-aged women: results from the Study of Women's Health Across the Nation (SWAN)Menopause, 2005
- Women's sexual dysfunction: revised and expanded definitionsCMAJ : Canadian Medical Association Journal, 2005
- Perimenopausal androgen decline after oophorectomy does not influence sexuality or psychological well-beingFertility and Sterility, 2005
- A Swedish Telephone Help-Line for Sexual Problems: A 5-Year SurveyThe Journal of Sexual Medicine, 2004
- Standards for Clinical Trials in Sexual Dysfunctions of Women: Research Designs and Outcomes AssessmentThe Journal of Sexual Medicine, 2004
- Validation of the Profile of Female Sexual Function (PFSF) in Surgically and Naturally Menopausal WomenJournal of Sex & Marital Therapy, 2004
- Addition of testosterone to estrogen replacement therapy in oophorectomized women: effects on sexuality and well-beingClimacteric, 2002
- Is sexual life influenced by transdermal estrogen therapy?Acta Obstetricia et Gynecologica Scandinavica, 1993
- Essentials of Psychological TestingThe American Journal of Psychology, 1960